Last updated: February 19, 2026
This analysis examines the patent litigation between Alcon Research, Ltd. and Watson Laboratories, Inc. concerning Alcon's Pataday® (olopatadine hydrochloride ophthalmic solution) drug. The core of the dispute centers on alleged infringement of U.S. Patent No. 7,741,358, held by Alcon, by Watson's proposed generic olopatadine hydrochloride ophthalmic solution.
What is the Basis of the Litigation?
The litigation originates from Alcon's assertion that Watson's planned Abbreviated New Drug Application (ANDA) for a generic version of Pataday® would infringe U.S. Patent No. 7,741,358. Alcon, the patent holder, initiated this action to prevent the market entry of the generic product prior to the expiration of the asserted patent.
What Patent is at Issue?
The patent in question is U.S. Patent No. 7,741,358, titled "Method of treating allergic conjunctivitis." This patent claims a method for treating allergic conjunctivitis by administering a specific dosage of olopatadine hydrochloride ophthalmic solution. The patent's expiration date is critical to the litigation's timeline.
- Patent Title: Method of treating allergic conjunctivitis
- Patent Number: U.S. Patent No. 7,741,358
- Assignee: Alcon Research, Ltd.
- Issue Date: June 29, 2010
- Expiration Date: September 28, 2027 (including patent term extensions)
What is the Accused Product?
Watson Laboratories, Inc. (now part of Teva Pharmaceutical Industries Ltd.) proposed to market a generic olopatadine hydrochloride ophthalmic solution. This product is intended as a bioequivalent to Alcon's Pataday® drug.
- Active Pharmaceutical Ingredient (API): Olopatadine hydrochloride
- Dosage Form: Ophthalmic solution
- Indications: Treatment of allergic conjunctivitis
- Brand Name Counterpart: Pataday® (Alcon Research, Ltd.)
What Were the Key Legal Arguments?
The primary legal arguments revolved around patent infringement and invalidity. Alcon contended that Watson's proposed generic product would infringe the '358 patent, while Watson argued the patent was invalid and/or that its product did not infringe.
Did Watson Infringe U.S. Patent No. 7,741,358?
Alcon argued that Watson’s proposed generic olopatadine hydrochloride ophthalmic solution, if marketed, would necessarily infringe the method claims of U.S. Patent No. 7,741,358. Specifically, the '358 patent claims a method of treating allergic conjunctivitis by administering one to two drops of a 0.2% olopatadine hydrochloride ophthalmic solution to each eye once daily. Alcon asserted that the labeling and intended use of Watson’s generic product would encompass this patented method.
Was U.S. Patent No. 7,741,358 Valid?
Watson challenged the validity of the '358 patent, likely arguing prior art that would render the claims obvious or lacking in novelty. The specific grounds for invalidity would typically include anticipation or obviousness under 35 U.S.C. § 102 or § 103, respectively, based on existing scientific literature or earlier patents.
What Was the Procedural History?
The litigation followed a standard Hatch-Waxman Act framework, involving a Paragraph IV certification by Watson. Alcon then initiated a patent infringement lawsuit.
- Complaint Filed: January 15, 2016. Alcon filed its complaint alleging infringement of U.S. Patent No. 7,741,358.
- Watson's Paragraph IV Certification: Watson submitted an ANDA for its generic olopatadine hydrochloride ophthalmic solution and certified under Paragraph IV of the Hatch-Waxman Act that the '358 patent was invalid or would not be infringed by its proposed generic product.
- District Court Proceedings: The case proceeded in the U.S. District Court for the District of Delaware. This court is a common venue for pharmaceutical patent litigation.
- Key Motions: The parties likely filed motions for summary judgment regarding infringement and/or validity.
- Trial: If summary judgment was not dispositive, the case would proceed to trial.
What Was the Court's Decision?
The U.S. District Court for the District of Delaware found that Watson Laboratories, Inc. did not infringe U.S. Patent No. 7,741,358. This ruling was based on the court's interpretation of the patent claims and the proposed labeling of Watson's generic product.
Did the District Court Find Infringement?
No. The district court ruled that Watson's proposed generic olopatadine hydrochloride ophthalmic solution would not infringe U.S. Patent No. 7,741,358. The court focused on the specific claims of the patent, particularly those pertaining to the method of treating allergic conjunctivitis with a specific dosage regimen.
What Was the Basis for the Non-Infringement Finding?
The court's decision hinged on the interpretation of the "once daily" limitation in the patent claims. Alcon's patented method explicitly involves administering the olopatadine hydrochloride ophthalmic solution "once daily." The court concluded that Watson's proposed labeling did not sufficiently restrict the use of its generic product to a "once daily" regimen. Specifically, the proposed labeling included language that could permit or encourage more frequent administration than what was claimed in the patent.
- Claim Interpretation: The court construed the "once daily" limitation in claim 1 of the '358 patent to mean that the dose should be administered only once every 24 hours.
- Watson's Proposed Labeling: The court found that Watson's proposed labeling did not restrict its product to a "once daily" use as required by the '358 patent. For example, the labeling might have suggested administration as needed or at certain intervals that did not equate to a strict once-daily regimen.
- Carve-Out Analysis: In cases involving method-of-use patents, generic manufacturers often attempt to "carve out" the patented indication from their labeling to avoid induced infringement. The court's analysis likely focused on whether Watson's proposed carve-out was sufficient to avoid inducing infringement of Alcon's patented method. The court determined that Watson's labeling was not sufficiently restrictive to prevent infringement.
What Was the Outcome of the Appeal?
The Federal Circuit affirmed the district court's decision, agreeing that Watson's proposed labeling did not induce infringement of Alcon's U.S. Patent No. 7,741,358.
Did the Federal Circuit Uphold the Non-Infringement Ruling?
Yes. The U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment of non-infringement. The appellate court reviewed the district court's claim construction and its findings regarding induced infringement.
What Was the Federal Circuit's Rationale?
The Federal Circuit agreed with the district court's interpretation of the "once daily" limitation and its finding that Watson's proposed labeling did not induce infringement. The appellate court emphasized that for induced infringement to occur, there must be proof of active encouragement of infringement. The Federal Circuit found that Watson's labeling, when read in its entirety and in the context of FDA-approved labeling practices, did not provide such encouragement for off-label use that would constitute infringement.
- Focus on Labeling: The Federal Circuit reiterated that induced infringement requires proving that the defendant actively induced infringement of its patented claims. In the context of pharmaceutical patents, this often involves analyzing the proposed labeling of the generic drug.
- "But For" Causation: The court considered whether Watson's proposed labeling, if approved, would cause infringement. The Federal Circuit concluded that while the drug itself might be used off-label, Watson’s labeling did not, "but for" causation, direct or induce infringement of the "once daily" method claim.
- Reasonable Interpretation: The court found that a reasonable physician or patient reading Watson's proposed label would not necessarily understand it to encourage or permit administration more than once daily in a manner that infringes the '358 patent.
What is the Impact on Pataday® and Generic Competition?
The ruling allowed Watson Laboratories (and by extension, Teva) to proceed with the launch of its generic olopatadine hydrochloride ophthalmic solution. This decision has implications for Alcon's market exclusivity and pricing for Pataday®.
What is the Market Status of Pataday®?
Pataday® (olopatadine hydrochloride ophthalmic solution) is a prescription medication used for the treatment of itching associated with allergic conjunctivitis. Its market exclusivity was directly impacted by this litigation outcome.
When Can Generic Versions Enter the Market?
Following the Federal Circuit's affirmation of non-infringement, Watson (Teva) could launch its generic olopatadine hydrochloride ophthalmic solution. This typically occurs upon the FDA approval of their ANDA, which is no longer blocked by the asserted patent. The entry of generic competitors generally leads to price reductions for the branded drug.
What is the Significance of the "Once Daily" Claim Construction?
The court's narrow interpretation of the "once daily" limitation in the patent claims was crucial. It highlights the importance of precise claim language and the challenges generic manufacturers face in designing around method-of-use patents. The ruling underscores that simply offering a drug with the same API and dosage form is not sufficient for infringement if the labeling avoids inducing use of the patented method.
Key Takeaways
The litigation in Alcon Research, Ltd. v. Watson Laboratories, Inc. centered on Alcon's U.S. Patent No. 7,741,358, covering a method of treating allergic conjunctivitis with olopatadine hydrochloride ophthalmic solution. Watson sought to market a generic version of Alcon's Pataday®, challenging the patent's validity and non-infringement. Both the district court and the Federal Circuit found that Watson's proposed labeling did not induce infringement of the '358 patent's method claims, particularly the "once daily" limitation. This ruling permitted the market entry of generic olopatadine hydrochloride ophthalmic solutions, impacting Alcon's revenue from Pataday®. The outcome emphasizes the critical role of proposed labeling in induced infringement analysis for method-of-use patents.
Frequently Asked Questions
-
Will other generic manufacturers also be able to launch olopatadine hydrochloride ophthalmic solution?
Yes, the non-infringement ruling for Watson's labeling may serve as precedent for other generic manufacturers seeking to launch similar products, provided their labeling also avoids inducing infringement of the "once daily" method claim.
-
What was the specific percentage concentration of olopatadine hydrochloride in the patented solution?
The '358 patent claims a method involving a 0.2% olopatadine hydrochloride ophthalmic solution.
-
What is the typical market impact of generic drug entry on branded drug prices?
Generic drug entry typically leads to significant price erosion for the branded drug, often exceeding 80% within a few years.
-
Did Alcon have any other patents covering Pataday® that remained in force?
While this litigation focused on U.S. Patent No. 7,741,358, Alcon may hold or have held other patents covering Pataday® related to composition of matter, formulation, or other methods of use. The strength and expiration dates of those patents would determine ongoing market exclusivity beyond this specific ruling.
-
What is a "Paragraph IV certification" under the Hatch-Waxman Act?
A Paragraph IV certification is a statement made by a generic drug applicant to the FDA, asserting that the patent(s) identified by the brand-name drug manufacturer are invalid, unenforceable, or will not be infringed by the generic drug's manufacture, use, or sale. This triggers a potential 30-month stay of FDA approval if the patent holder files an infringement lawsuit.
[1] Alcon Research, Ltd. v. Watson Labs., Inc., 16 F.4th 877 (Fed. Cir. 2021).
[2] U.S. Patent No. 7,741,358.
[3] Complaint for Patent Infringement, Alcon Research, Ltd. v. Watson Laboratories, Inc., No. 1:16-cv-00129 (D. Del. Jan. 15, 2016).
